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TO THE EDITOR
Dominantly inherited epidermolysis
bullosa simplex type Dowling-Meara
(EBS-DM) is caused by mutations in
either the keratin 5 (K5) or the keratin
14 (K14) gene, which encode the major
components of the intermediate filament
(IF) network in basal keratinocytes.
In healthy keratinocytes, heterodimers
of K5 and K14 polymerize to form a
cytoplasmic network extending to the
cellular periphery and imparting stabi-
lity to the basal layer of the stratified
epithelia. In EBS-DM, causative muta-
tions lead to disintegration and collapse
of the IF network, which manifests
cytologically as electron-dense aggre-
gates at the periphery of the keratino-
cyte cytoplasm (Morley et al., 2003).
EBS-DM cells exhibit increased fragility
to mechanical stress as well as to heat
and osmotic shock, making Dowling-
Meara the most severe subtype of EBS.
As a consequence, EBS-DM patients
suffer from blistering and wounding
of the skin and mucous membranes
after even minor trauma (Stephens
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Figure 1. Epidermolysis bullosa simplex type Dowling-Meara (EBS-DM) expression profiles and response to IL-1b inhibition. (a) Expression of K14, JNK, and
IL-1b was analyzed in EBS-DM immortalized keratinocyte cell lines (KEB-7, EBDM-1), in primary EBS-DM keratinocytes (PEBDM-1), and in wild-type
immortalized keratinocytes (NEB-1) expressing a full-length K14 cDNA harboring the EBS-DM mutation R125P. Results are normalized to wild-type NEB-1
immortalized keratinocytes and given as fold changes. (b) Increased expression of K14 was also detected by western blot analysis, using annexin-I (ANXAI) as a
loading control. Band intensities were quantified using Image Lab software and are given as fold changes over NEB-1. (c) Activated IL-1b was measured in an
ELISpot assay of untreated and lipopolysaccharide (LPS)-induced keratinocytes and are presented as spot-forming units (sfu) per well. (d) At the messenger RNA
level, K14, JNK, and IL-1b expression all decreased in patient-derived immortalized cell lines KEB-7 and EBDM-1 upon treatment with IL-1bAb. Percent expression
levels are given in relation to untreated keratinocytes (untreated: 100% expression). (e) Also, upon treatment with diacerein, K14 and JNK levels decreased.
(f) pJNK and K14 levels decreased upon treatment with IL-1bAb (Ab) or diacerein (Dia). Statistical significance: *Po0.05; **Po0.01; ***Po0.005.
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et al., 1993; D’Alessandro et al., 2002;
Coulombe et al., 2009; Jerabkova et al.,
2010). Interestingly, upregulation of
K14 at both the transcriptional and
protein levels was shown recently in
EBS-DM keratinocytes (Wally et al.,
2010; Beriault et al., 2012). The JNK/
MAPK stress pathway is also known to
be upregulated in EBS-DM keratino-
cytes, and the cells show elevated JNK
phosphorylation compared to clinically
milder, K14-based EBS subtypes
(D’Alessandro et al., 2002). Particularly
with regard to a small molecule-based
therapeutics, we have focused on
the pathomechanism underlying K14
overexpression and aggregation. We
have investigated the potential involve-
ment of the pro-inflammatory cytokine
IL-1b in EBS-DM pathology. IL-1b
is secreted by keratinocytes (and
other cell types) and binds to specific
receptors of basal keratinocytes,
activating those cells in response to
wounding. Activated keratinocytes
exhibit higher migratory potential and
hyperproliferative activity, and secrete
extracellular-matrix components and
signaling polypeptides to the tissue
microenvironment (Freedberg et al.,
2001). Defects in these processes
could also contribute to the EBS-DM
phenotype.
To examine whether the presence
of EBS-DM underlying mutations in the
K14 gene is directly linked to the IL-1b-
mediated JNK stress pathway, we
compared K14, IL-1b, and JNK messen-
ger RNA (mRNA) levels in two immor-
talized EBS-DM cell lines (KEB-7,
EBDM-1), primary EBS-DM keratino-
cytes (PEBDM-1), and wild-type
immortalized NEB-1 keratinocytes by
using semiquantitative real-time PCR
(SQRT-PCR). We also engineered NEB-
1 keratinocytes to express a full-length
K14 cDNA harboring an EBS-DM muta-
tion (R125P) in exon 1 and examined
those cells by SQRT-PCR as well. As
expected, K14 expression was elevated
in all EBS-DM keratinocytes. In addi-
tion, significant upregulation of JNK and
IL-1b mRNA expression was detected
(Figure 1a), except for JNK expression
in PEBDM-1, where results varied in
SQRT-PCR, resulting in a P-value of
0.34. However, PEBDM-1 keratino-
cytes, as well as all EBS-DM cell lines,
showed a clear increase of phopho-JNK
levels in western blot analysis (data not
shown). Furthermore, upregulation of
K14 protein was shown in all cell lines
and PEBDM-1 keratinocytes (Figure 1b).
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Figure 2. Decreased invasiveness and increased stability of the intermediate filament (IF) network upon IL-1b inhibition in patient keratinocytes. (a) Matrigel
invasion assay was performed with wild-type NEB-1 keratinocytes as well as with patient KEB-7 and EBDM-1 keratinocytes. KEB-7 and EBDM-1 cells are much
more invasive than NEB-1 cells (invasiveness is given as the percentage of cells that invaded through the matrigel). Addition of IL-1b neutralizing antibody to the
medium caused a reduction of invasiveness by over 70% (statistics: **Po0.01; ***Po0.005; DPo0.001). (b) Immunofluorescent staining of K14 revealed increased
stability of the IF network of KEB-7 after a 30-min heat shock in the presence of either Il-1bAb or diacerein. Note that in NEB-1 cells the IF network remains intact
after the heat shock, whereas in untreated KEB-7 cells characteristic aggregates are detectable in the periphery of the cytoplasm. Ab, antibody. Bar¼ 10mm.
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In patient immortalized cell lines,
increased production of secreted IL-1b
was shown in an ELISpot assay (Figure 1c).
With a view toward small-molecule
therapeutics, we investigated the ability
of IL-1b neutralizing antibody (IL-1bAb)
and diacerein to inhibit IL-1b signaling.
Diacerein, a component of rhubarb
root, is reported to block the release
of active IL-1b by inhibiting plasma
membrane-bound IL-1 converting
enzyme (Moldovan et al., 2000;
Verbruggen, 2000). We tested both
substances in an in vitro setting to
investigate their ability to ameliorate
EBS-DM pathology at the cellular level.
Treatment of KEB-7 and EBDM-1 with
2mg ml 1 IL-1bAb for 24 h resulted in
significant downregulation of K14,
JNK, and IL-1b expression compared to
non-treated keratinocytes, as measured
by SQRT-PCR (Figure 1d). Similarly,
when the same cell lines were treated
with 10mg ml1 diacerein, K14 and
JNK expression levels went down
(Figure 1e). However, because diacerein
exerts its effect on IL-1b at the post-
translational level, we observed no
effect on IL-1b at the transcriptional
level at 24 h. At the protein level, both
K14 and phospho-JNK levels decreased
upon treatment with IL-1bAb or diacer-
ein (Figure 1f). In contrast, in NEB-1
cells treated with recombinant IL-1b the
expression levels of K14, IL-1b, and JNK
all increased (data not shown). Because
many genes encoding matrix-degrading
proteins (eg, MMPs, KLKs) are targets
of the IL-1b signaling pathway and are
upregulated in EBS-DM (data not
shown), we performed an invasion assay
to measure keratinocyte invasiveness
upon IL-1b inhibition (Liacini et al.,
2002). Whereas untreated EBDM-1
and KEB-7 cells showed significantly
increased invasive potential over NEB-1
wild-type keratinocytes, a significant
decrease in invasiveness was detected
upon treatment with IL-1bAb (Figure 2a),
accompanied by downregulation of
matrix-degrading proteins (data not
shown). In addition, we examined K14
aggregation in the cytoplasm of heat-
shocked wild-type and EBS-DM kerati-
nocytes in the presence or absence
of IL-1bAb or diacerein (Figure 2b).
Characteristic aggregates were detected
by immunofluorescence microscopy in
about 10% of all KEB-7 keratinocytes,
accompanied by upregulation of K14,
IL-1b, and JNK expression (data not
shown). In contrast, no aggregates at
all formed in NEB-1 cells or in KEB-7
cells treated with IL-1bAb or diacerein.
This leads us to hypothesize that aggre-
gation of K14 is a key event in the
induction of IL-1b and the JNK stress
pathway.
To summarize, we showed here that,
in EBS-DM keratinocytes, IL-1b signal-
ing is constitutively activated, resulting
in activation of the JNK stress pathway
and overexpression of K14 and IL-1b
itself in a positive feedback loop.
Through this mechanism, expression of
the dominantly interfering mutated K14
allele would also increase, potentially
aggravating the EBS-DM phenotype.
Therefore, therapeutic approaches
to interrupt this positive feedback loop
by inhibiting IL-1b using a neutralizing
antibody or diacerein would seem
worthwhile. Indeed, treatment of patient
keratinocytes with these agents not only
reduced the expression levels of K14
and IL-1b and the phosphorylation
levels of JNK, but also stabilized the
IF network upon heat shock. Our data
are further corroborated by our recent
demonstration that overall K14 expres-
sion levels in EBS-DM keratinocytes are
reduced upon mRNA correction via
spliceosome-mediated RNA trans-
splicing (SMaRT), which shifts the
expression ratio of wild-type versus
mutated K14 alleles toward wild-type
(Wally et al., 2010). We therefore
propose that inhibition of IL-1b could
be beneficial to EBS-DM patients by
ameliorating the EBS-DM phenotype.
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